Epilepsy Pipeline Grows as 75+ Pharma Companies Advance 90+ Novel Therapies for Seizure Management, Finds DelveInsight | Harmony Biosciences, Stoke Therapeutics, Xenon Pharmaceuticals, Neurona Therapeutics, Praxis Precision Medicines

DelveInsight's "Epilepsy - Pipeline Insight, 2026" report provides comprehensive insights about 75+ companies developing several pipeline drugs in the Epilepsy pipeline landscape. It covers the epilepsy pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Epilepsy treatment landscape. Learn more about the evolving epilepsy pipeline today @ https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways and Recent Developments from the Epilepsy Pipeline Report

• In April 2025, Neurona Therapeutics reported new results from its early-stage clinical trial of NRTX-1001, an experimental cell therapy for adults with drug-resistant mesial temporal lobe epilepsy (MTLE).
• In April 2025, IAMA Therapeutics secured approximately 18 million USD in funding to advance its neuroscience pipeline, including lead candidate IAMA-6, which is currently in a Phase I clinical trial.
• In January 2024, the Epilepsy Foundation research was reviewed to provide updates on new drugs, supplements, and tools within the community-supported tracker.
• By the end of 2023, Xenon Pharmaceuticals planned to initiate Phase II-III trials for XEN1101 after demonstrating a 53% reduction in monthly seizure counts in high-dose clinical evaluations.
• The upcoming 2026 Epilepsy Pipeline Conference, scheduled for June 18-19, 2026, will serve as a forum for evaluating new therapies and exploring AI transformations in care.
• Epilepsy affects over 50 million people worldwide, and with 30-40% of patients unresponsive to existing drugs, there is a significant shift toward precise genetic targets and disease-modifying therapies.
• Leading epilepsy companies advancing the pipeline include Harmony Biosciences, Stoke Therapeutics, Xenon Pharmaceuticals, Neurona Therapeutics, Praxis Precision Medicines, Ovid Therapeutics, and Marinus Pharmaceuticals.

Download for updates and the latest revolution in epilepsy care @ https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Epilepsy Emerging Drugs Profile

• XEN1101: Xenon Pharmaceuticals
XEN1101 is a next-generation potassium channel opener that has demonstrated high potency at Kv7 channels in preclinical and clinical evaluations. Clinical data showed a robust 53% reduction in monthly seizure counts compared to 18% for placebo, with the benefit observed as early as the first week of treatment. The drug is designed for once-daily oral dosing without titration, significantly improving patient convenience compared to earlier-generation agents. XEN1101 is currently moving into Phase II-III clinical trials for adult focal epilepsy.

• NRTX-1001: Neurona Therapeutics
NRTX-1001 is a first-in-class regenerative cell therapy consisting of inhibitory neurons designed to repair hyperexcitable neural networks. In clinical trials for drug-resistant mesial temporal lobe epilepsy (MTLE), it has shown promise in providing long-term seizure suppression. Recent data reported in April 2025 further support its safety and efficacy in adults who have failed conventional pharmacological treatments. NRTX-1001 is currently in Phase I/II clinical evaluation.

• Vormatrigine: Praxis Precision Medicines
Vormatrigine is a functionally selective small molecule targeting the hyperexcitable state of sodium channels in the brain. Developed as a once-daily oral treatment, it aims to be best-in-class for focal onset seizures and generalized epilepsy. Results from the RADIANT study demonstrated robust seizure reduction and a favorable drug-drug interaction profile, supporting its use in combination with other anti-seizure medications. It is currently being advanced through clinical evaluations for treatment-resistant epilepsy.

For more information on the Epilepsy Emerging Drugs Profile, download DelveInsight's comprehensive Epilepsy Pipeline Insight report @ https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Epilepsy Pipeline Report Provides

• Detailed insights about 75+ companies developing therapies for Epilepsy, including aggregate therapies developed by each player.
• Coverage of over 90 pipeline drugs segmented into early-stage, mid-stage, and late-stage clinical development.
• Assessment of drugs based on stage, route of administration (oral, intravenous, etc.), and molecule type (small molecules, gene therapies, etc.).
• Detailed analysis of commercial activities including collaborations, licensing agreements, and financing to support therapeutic advancement.

Learn more about Epilepsy drug opportunities in our comprehensive epilepsy pipeline report @ https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Epilepsy Companies and Competitive Landscape

There are 75+ key companies developing therapies for Epilepsy, with major players including Harmony Biosciences, Stoke Therapeutics, Xenon Pharmaceuticals, Neurona Therapeutics, and Praxis Precision Medicines. These companies are addressing a critical market need where 30% to 40% of patients remain refractory to existing treatments.

DelveInsight's Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Epilepsy products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Epilepsy treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Epilepsy Pipeline Report

• Coverage: Global
• Epilepsy Companies: Harmony Biosciences, Stoke Therapeutics, Xenon Pharmaceuticals, Neurona Therapeutics, Praxis Precision Medicines, and others.
• Epilepsy Therapies: XEN1101, NRTX-1001, Vormatrigine, EPX-100, STK-001, and others.
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.